Skip to main content
. 2022 Jan 26;64(1):5413. doi: 10.4102/safp.v64i1.5413

TABLE 1.

The REVERT trial – Primary and secondary outcomes.

Outcome Standard VM
Modified VM
Effect size
n (214) % Median IQR n (214) % Median IQR OR 95% CI Median IQR p
Presence of sinus rhythm at 1 min 37 17 - - 93 43 - - 3.7 2.3–5.8 - - < 0.0001
Adenosine needed 148 69 - - 108 50 - - 0.45 0.30–0.68 - - 0.0002
Any other emergency anti-arrhythmic needed 171 80 - - 121 57 - - 0.33 0.21–0.51 - - < 0.0001
Discharged home from emergency room 146 68 - - 134 63 - - 0.79 0.51–1.21 - - 0.28
Any adverse events 8 4 - - 13 6 - - 1.61 0.63–4.08 - - 0.32
Time spent in emergency room (h) - - 2.83 1.05–3.62 - - 2.82 1.95–3.77 - - 0.90 0.75–1.10 0.31

Source: Adapted from Appelboam A, Reuben A, Mann C, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): A randomised controlled trial. Lancet. 2015;386(10005):1747–1753. https://doi.org/10.1161/01.CIR.98.24.2716

VM, Valsalva manoeuvre; CI, confidence interval; IQR, interquartile range; OR, odds ratio.